Evidence map›Paper›PMID 25538692›Full record

ArticleFrontiers in microbiology2014

Antifungal amphiphilic aminoglycoside K20: bioactivities and mechanism of action.

Sanjib K Shrestha, Cheng-Wei T Chang, Nicole Meissner, John Oblad, Jaya P Shrestha, Kevin N Sorensen, Michelle M Grilley, Jon Y Takemoto

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 36 citations in OpenAlex.

  1. Identification of NovelMicroorganisms · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Aminoglycoside-Induced Cochleotoxicity: A Review.Frontiers in cellular neuroscience · 2017
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sanjib K ShresthaDepartment of Biology, Utah State University Logan, UT, USA ; Synthetic Bioproducts Center, Utah State University North Logan, UT, USA.
Cheng-Wei T ChangSynthetic Bioproducts Center, Utah State University North Logan, UT, USA ; Department of Chemistry and Biochemistry, Utah State University Logan, UT, USA.
Nicole MeissnerDepartment of Immunology and Infectious Diseases, Montana State University Bozeman, MT, USA.
John ObladDepartment of Chemistry and Biochemistry, Utah State University Logan, UT, USA.
Jaya P ShresthaDepartment of Chemistry and Biochemistry, Utah State University Logan, UT, USA.
Kevin N SorensenDepartment of Biology, Snow College Ephraim, UT, USA.
Michelle M GrilleyDepartment of Biology, Utah State University Logan, UT, USA.
Jon Y TakemotoDepartment of Biology, Utah State University Logan, UT, USA ; Synthetic Bioproducts Center, Utah State University North Logan, UT, USA.
Utah State University · USMontana State University · USSnow College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

K20 is a novel amphiphilic antifungal aminoglycoside that is synthetically derived from the antibiotic kanamycin A. Reported here are investigations of K20's antimicrobial activities, cytotoxicity, and fungicidal mechanism of action. In vitro growth inhibitory activities against a variety of human and plant pathogenic yeasts, filamentous fungi, and bacteria were determined using microbroth dilution assays and time-kill curve analyses, and hemolytic and animal cell cytotoxic activities were determined. Effects on Cryptococcus neoformans H-99 infectivity were determined with a preventive murine lung infection model. The antifungal mechanism of action was studied using intact fungal cells, yeast lipid mutants, and small unilamellar lipid vesicles. K20 exhibited broad-spectrum in vitro antifungal activities but not antibacterial activities. Pulmonary, single dose-administration of K20 reduced C. neoformans lung infection rates 4-fold compared to controls. Hemolysis and half-maximal cytotoxicities of mammalian cells occurred at concentrations that were 10 to 32-fold higher than fungicidal MICs. With fluorescein isothiocyanate (FITC), 20-25 mg/L K20 caused staining of >95% of C. neoformans and Fusarium graminearum cells and at 31.3 mg/L caused rapid leakage (30-80% in 15 min) of calcein from preloaded small unilamellar lipid vesicles. K20 appears to be a broad-spectrum fungicide, capable of reducing the infectivity of C. neoformans, and exhibits low hemolytic activity and mammalian cell toxicity. It perturbs the plasma membrane by mechanisms that are lipid modulated. K20 is a novel amphiphilic aminoglycoside amenable to scalable production and a potential lead antifungal for therapeutic and crop protection applications.

Indexed as

amphiphilic aminoglycosideantifungalCryptococcus neoformansK20kanamycin

Identifiers

PMID25538692
PMCPMC4257101
OpenAlexW2047785004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.